WO2005035574A1 - IgM高濃度安定化溶液 - Google Patents
IgM高濃度安定化溶液 Download PDFInfo
- Publication number
- WO2005035574A1 WO2005035574A1 PCT/JP2004/014935 JP2004014935W WO2005035574A1 WO 2005035574 A1 WO2005035574 A1 WO 2005035574A1 JP 2004014935 W JP2004014935 W JP 2004014935W WO 2005035574 A1 WO2005035574 A1 WO 2005035574A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- igm
- concentration
- ion
- nacl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/575,192 US20070212346A1 (en) | 2003-10-09 | 2004-10-08 | Highly Concentrated Stabilized Igm Solution |
EP04792204A EP1688432B1 (en) | 2003-10-09 | 2004-10-08 | Igm high concentration stabilized solution |
AT04792204T ATE518888T1 (de) | 2003-10-09 | 2004-10-08 | Stabilisierte lösung mit hoher igm-konzentration |
JP2005514615A JP4762717B2 (ja) | 2003-10-09 | 2004-10-08 | IgM高濃度安定化溶液 |
US12/509,075 US8920797B2 (en) | 2003-10-09 | 2009-07-24 | Highly concentrated stabilized IgM solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-351388 | 2003-10-09 | ||
JP2003351388 | 2003-10-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/575,192 A-371-Of-International US20070212346A1 (en) | 2003-10-09 | 2004-10-08 | Highly Concentrated Stabilized Igm Solution |
US12/509,075 Continuation US8920797B2 (en) | 2003-10-09 | 2009-07-24 | Highly concentrated stabilized IgM solution |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005035574A1 true WO2005035574A1 (ja) | 2005-04-21 |
Family
ID=34431075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014935 WO2005035574A1 (ja) | 2003-10-09 | 2004-10-08 | IgM高濃度安定化溶液 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20070212346A1 (ja) |
EP (1) | EP1688432B1 (ja) |
JP (1) | JP4762717B2 (ja) |
AT (1) | ATE518888T1 (ja) |
WO (1) | WO2005035574A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007076062A2 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
JP2010511665A (ja) * | 2006-12-05 | 2010-04-15 | クルセル ホランド ベー ヴェー | 液体抗狂犬病抗体製剤 |
US7709615B2 (en) | 2003-07-15 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides encoding anti-ganglioside antibodies |
US7803914B2 (en) | 2003-10-09 | 2010-09-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for stabilizing protein solutions |
WO2011093083A1 (ja) * | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
JP2012501332A (ja) * | 2008-08-27 | 2012-01-19 | シェーリング コーポレイション | 操作された抗IL−23p19抗体の凍結乾燥製剤 |
JP2013525484A (ja) * | 2010-05-03 | 2013-06-20 | ジェネンテック, インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
US8920797B2 (en) | 2003-10-09 | 2014-12-30 | Chugai Seiyaku Kabushiki Kaisha | Highly concentrated stabilized IgM solution |
US9278131B2 (en) | 2012-08-10 | 2016-03-08 | Adocia | Process for lowering the viscosity of highly concentrated protein solutions |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ598881A (en) * | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JP2023532473A (ja) * | 2020-07-10 | 2023-07-28 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | ヒト血漿由来免疫グロブリンmを含む組成物を得るための方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02493A (ja) * | 1987-08-10 | 1990-01-05 | Miles Inc | 精製されたIgM |
JPH0278635A (ja) * | 1988-07-27 | 1990-03-19 | Biotest Ag | IgMを含有する静脈内投与のポリクローナル免疫グロブリン調製物の調製方法 |
JPH09127112A (ja) * | 1995-10-30 | 1997-05-16 | Dainabotsuto Kk | 修飾IgM免疫学的測定試薬 |
JPH09127114A (ja) * | 1995-11-01 | 1997-05-16 | Dainabotsuto Kk | 免疫学的測定用安定化IgM試薬 |
JP2001504092A (ja) * | 1996-10-14 | 2001-03-27 | ロトクレーツシュティフツング・ゼントラルラボラトリウム・ブルツペンディエンシュト・エス・アール・ケイ | 静脈内適用のためのIgM製剤の製造方法 |
WO2002096457A2 (en) | 2001-05-31 | 2002-12-05 | Novartis Ag | Stable liquid formulations of antibodies |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5157113A (en) * | 1987-08-10 | 1992-10-20 | Miles Inc. | Removal of nucleic acids from monoclonal antibody preparations |
GB8719963D0 (en) | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
US6238891B1 (en) | 1987-11-18 | 2001-05-29 | Cetus Oncology Corporation | Method of increasing product expression through solute stress |
CA1312030C (en) | 1987-11-18 | 1992-12-29 | Brian Maiorella | Method to increase antibody titer |
JP2501116B2 (ja) | 1988-03-05 | 1996-05-29 | 日本電信電話株式会社 | 巡回制御形回線交換方法 |
FR2655341B1 (fr) * | 1989-12-01 | 1992-02-21 | Rhone Poulenc Sante | Derives dihydropyranniques, leurs procedes de preparation et leur utilisation. |
GB9010944D0 (en) | 1990-05-16 | 1990-07-04 | Central Blood Lab Authority | Chemical compounds |
US5419904A (en) | 1990-11-05 | 1995-05-30 | The Regents Of The University Of California | Human B-lymphoblastoid cell line secreting anti-ganglioside antibody |
JPH05192181A (ja) | 1990-12-18 | 1993-08-03 | Ishihara Sangyo Kaisha Ltd | ヒトモノクローナル抗体 |
EP0492409A1 (en) | 1990-12-18 | 1992-07-01 | Ishihara Sangyo Kaisha, Ltd. | Human monoclonal antibody |
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
AU660981B2 (en) | 1991-03-12 | 1995-07-13 | Astellas Us Llc | CD2-binding domain of lymphocyte function associated antigen 3 |
JPH04360696A (ja) | 1991-06-06 | 1992-12-14 | Sumitomo Chem Co Ltd | 新規なヒトbリンパ細胞株を宿主として産生された組み換えヒト抗体 |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
JP3565572B2 (ja) | 1992-09-07 | 2004-09-15 | 協和醗酵工業株式会社 | ヒト化抗体 |
US5830470A (en) | 1992-09-07 | 1998-11-03 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
JPH06178689A (ja) | 1992-12-11 | 1994-06-28 | Mitsui Toatsu Chem Inc | I型緑膿菌を抗原とするヒト抗体をコードする遺伝子 |
JPH06189781A (ja) | 1992-12-25 | 1994-07-12 | Mitsui Toatsu Chem Inc | 培養液中の生理活性タンパク質の安定化方法 |
WO1998006749A2 (en) | 1996-08-16 | 1998-02-19 | President And Fellows Of Harvard College | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
JPH10324699A (ja) | 1997-03-21 | 1998-12-08 | Sankyo Co Ltd | 抗ヒトFasヒト化抗体 |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
WO1999036105A2 (en) | 1998-01-16 | 1999-07-22 | Mca Development B.V. | USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE |
WO1999037329A1 (en) | 1998-01-22 | 1999-07-29 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
JP2002504342A (ja) | 1998-02-19 | 2002-02-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 一価mhc結合ドメイン融合タンパク質および接合体、多価mhc結合ドメイン融合タンパク質および接合体、ならびに多量体mhc結合ドメイン融合タンパク質および接合体、そしてそれらのための使用 |
JP2000154149A (ja) | 1998-09-18 | 2000-06-06 | Sankyo Co Ltd | 抗ヒトFasヒト化抗体含有抗リウマチ剤 |
ES2265693T3 (es) | 1998-10-16 | 2007-02-16 | Biogen Idec Ma Inc. | Proteinas de fusion con interferon-beta y usos. |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2000066160A1 (fr) | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation |
AU7449200A (en) | 1999-09-30 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Derivatives of antibody against ganglioside gm2 |
JP4851041B2 (ja) | 1999-11-05 | 2012-01-11 | 協和発酵キリン株式会社 | 細胞内のカルシウムイオンの濃度変化をモニターするトランスジェニック非ヒト哺乳動物 |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
WO2002010371A1 (fr) | 2000-08-01 | 2002-02-07 | Kyowa Hakko Kogyo Co., Ltd. | Peptide acitf sur le plan physiologique et utilisation de celui-ci |
JP2003128576A (ja) | 2001-10-25 | 2003-05-08 | Taisho Pharmaceut Co Ltd | エンドトキシン誘発性疾患治療薬 |
AU2002356749A1 (en) | 2001-11-28 | 2003-06-10 | Hermann Katinger | Process for the production of polypeptides in mammalian cell cultures |
EP2204190A1 (en) | 2003-07-15 | 2010-07-07 | Chugai Seiyaku Kabushiki Kaisha | IgM production by transformed cells and methods for quantifying said IgM production |
US20070212346A1 (en) | 2003-10-09 | 2007-09-13 | Tomoyuki Igawa | Highly Concentrated Stabilized Igm Solution |
JP4671864B2 (ja) | 2003-10-09 | 2011-04-20 | 中外製薬株式会社 | タンパク質溶液の安定化方法 |
-
2004
- 2004-10-08 US US10/575,192 patent/US20070212346A1/en not_active Abandoned
- 2004-10-08 JP JP2005514615A patent/JP4762717B2/ja not_active Expired - Fee Related
- 2004-10-08 EP EP04792204A patent/EP1688432B1/en not_active Not-in-force
- 2004-10-08 WO PCT/JP2004/014935 patent/WO2005035574A1/ja active Application Filing
- 2004-10-08 AT AT04792204T patent/ATE518888T1/de not_active IP Right Cessation
-
2009
- 2009-07-24 US US12/509,075 patent/US8920797B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02493A (ja) * | 1987-08-10 | 1990-01-05 | Miles Inc | 精製されたIgM |
JPH0278635A (ja) * | 1988-07-27 | 1990-03-19 | Biotest Ag | IgMを含有する静脈内投与のポリクローナル免疫グロブリン調製物の調製方法 |
JPH09127112A (ja) * | 1995-10-30 | 1997-05-16 | Dainabotsuto Kk | 修飾IgM免疫学的測定試薬 |
JPH09127114A (ja) * | 1995-11-01 | 1997-05-16 | Dainabotsuto Kk | 免疫学的測定用安定化IgM試薬 |
JP2001504092A (ja) * | 1996-10-14 | 2001-03-27 | ロトクレーツシュティフツング・ゼントラルラボラトリウム・ブルツペンディエンシュト・エス・アール・ケイ | 静脈内適用のためのIgM製剤の製造方法 |
WO2002096457A2 (en) | 2001-05-31 | 2002-12-05 | Novartis Ag | Stable liquid formulations of antibodies |
Non-Patent Citations (4)
Title |
---|
DRABER P. ET AL.: "Stability of monoclonal IgM antibodies freeze-dried in the presence of terhalose", J. IMMUNOL. METHODS, vol. 181, no. 1, 1995, pages 37 - 43, XP004021054 * |
GOMBOTZ W.R. ET AL.: "The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone)", PHARM. RES., vol. 11, no. 5, 1994, pages 624 - 632, XP002984460 * |
NATURE, vol. 321, 1986, pages 521 |
PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7709615B2 (en) | 2003-07-15 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides encoding anti-ganglioside antibodies |
US8257703B2 (en) | 2003-07-15 | 2012-09-04 | Chugai Seiyaku Kabushiki Kaisha | Anti-ganglioside antibodies and compositions |
US8920797B2 (en) | 2003-10-09 | 2014-12-30 | Chugai Seiyaku Kabushiki Kaisha | Highly concentrated stabilized IgM solution |
US7803914B2 (en) | 2003-10-09 | 2010-09-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for stabilizing protein solutions |
US7758860B2 (en) | 2005-12-21 | 2010-07-20 | Wyeth Llc | Protein formulations with reduced viscosity and uses thereof |
WO2007076062A2 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
JP2009521482A (ja) * | 2005-12-21 | 2009-06-04 | ワイス | 低粘度のタンパク質製剤およびその用途 |
US7390786B2 (en) | 2005-12-21 | 2008-06-24 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
WO2007076062A3 (en) * | 2005-12-21 | 2008-04-17 | Wyeth Corp | Protein formulations with reduced viscosity and uses thereof |
JP2010511665A (ja) * | 2006-12-05 | 2010-04-15 | クルセル ホランド ベー ヴェー | 液体抗狂犬病抗体製剤 |
JP2012501332A (ja) * | 2008-08-27 | 2012-01-19 | シェーリング コーポレイション | 操作された抗IL−23p19抗体の凍結乾燥製剤 |
JP2016028086A (ja) * | 2008-08-27 | 2016-02-25 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 操作された抗IL−23p19抗体の凍結乾燥製剤 |
WO2011093083A1 (ja) * | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
JP2013525484A (ja) * | 2010-05-03 | 2013-06-20 | ジェネンテック, インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
US9278131B2 (en) | 2012-08-10 | 2016-03-08 | Adocia | Process for lowering the viscosity of highly concentrated protein solutions |
Also Published As
Publication number | Publication date |
---|---|
JP4762717B2 (ja) | 2011-08-31 |
US8920797B2 (en) | 2014-12-30 |
EP1688432A1 (en) | 2006-08-09 |
US20070212346A1 (en) | 2007-09-13 |
EP1688432A4 (en) | 2007-09-12 |
US20090285802A1 (en) | 2009-11-19 |
ATE518888T1 (de) | 2011-08-15 |
JPWO2005035574A1 (ja) | 2008-02-14 |
EP1688432B1 (en) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8920797B2 (en) | Highly concentrated stabilized IgM solution | |
US10899841B2 (en) | Anti-BAFFR antibody formulations and methods of use thereof | |
US11612659B2 (en) | Anti-CD40 antibody formulation delivery device | |
EP2858671B1 (en) | Antibody formulation | |
EP2620450B1 (en) | Anti-CTLA-4 antibody compositions | |
RU2633509C2 (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
EP2473191B1 (en) | Antibody coformulations | |
WO2018121578A1 (zh) | 稳定的包含cd147单克隆抗体的药物制剂 | |
WO2019085982A1 (zh) | 一种抗pd-l1人源化单克隆抗体的药物组合物 | |
TW201028167A (en) | Pharmaceutical composition | |
CN111148510A (zh) | 用于治疗性蛋白质的冻干药物配制品的方法 | |
JP2021183611A (ja) | 組換えグリコシル化エクリズマブおよびエクリズマブ変異体 | |
US7803914B2 (en) | Methods for stabilizing protein solutions | |
WO2021244627A1 (zh) | 分离的抗原结合蛋白及其用途 | |
UA120164C2 (uk) | Стабільний склад на основі біспецифічного антитіла до il-4/il-13 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514615 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004792204 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004792204 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10575192 Country of ref document: US Ref document number: 2007212346 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10575192 Country of ref document: US |